Call Us Today:
949.200.1600

Bowen's Disease

Home >Diagnosis > Squamous Cell Carcinoma > Bowen's Disease

Bowens-Disease-Skin-Cancer-Specialists-Skin-Cancer-and-Reconstructive-Surgery-Center-Orange-County

About Bowen's Disease

Contact SCARS Center of Orange Country for Bowen’s disease treatment. Bowen’s disease or squamous cell carcinoma in situ is a cutaneous neoplasm with a 3-5% risk of invasive carcinoma. It is of particular interest due to the plethora of treatment modalities available. Sun exposure is one of the causes of Bowen’s carcinoma, but over ½ of cases have detectable oncogenic HPV types 16 and 18. The implication is that HPV-induced Bowen’s disease should be responsive to agents with antitumor and antiviral effect. Most therapeutic options for Bowen’s disease, except Mohs excision, have failure and recurrence rate of 10%-20%, and no treatment modality is best in all clinical scenarios. Our Newport Beach doctors work with each patient on an individual level.

About Bowen's Disease

5-fluorouracil (5-FU) is usually applied once or twice daily as a 5% cream for up to 2 months and can be repeated if needed. The median clearance rate with 5-FU among the studies is 80-90% with 10-20% recurrence rate. Although some show better and some worse results, the variability of treatment regimens and study design account for part of that. 5-FU can be an irritant affecting patient compliance. To limit irritation of treatment, less aggressive regimens have been employed with diminished clearance rates and long term control rates. In those cases additional cycles of treatment are needed to improve clearance and limit recurrence.

 

Imiquimod (Aldara) has the unique role as both an anti-tumor agent and an anti-viral agent given its immunomodulating action. This fits the large portion of Bowen’s disease, having an HPV association. Imiquimod applied daily for 16 weeks produced a cure rate between 73% and 93% in several studies. Like 5-FU, some imiquimod patients have significant skin reactions to treatment. These can be severe enough to stop the treatment prematurely.

 

An innovative approach obtained 100% cure rate utilizing cryoimmunotherapy in a single study. Liquid nitrogen cryospray was applied one week prior to a 6-week course of 5% imiquimod applied 5 of 7 days. A few patients required application of tretinoin 0.025% cream to incite a reaction by enhancing imiquimod penetration. The theory is that liquid nitrogen damages the integrity of the stratum corneum thereby facilitating cream penetration.¹

 

Cryotherapy alone also has a failure rate of up to 30%. However, success rate up to 90% at 12 months has been shown, provided that an adequate freeze-thaw cycle is applied. Examples of freeze-thaw cycles (FTC) are a single 30 second FTC, two 20 second FTC with a thaw period, or up to three single treatments of 20 seconds at intervals of several weeks. Although effective for smaller lesions, treatment of broad lesions or lower leg lesions may be impractical due to discomfort and slow healing. Curettage and cautery (electrodessication and curettage, ED&C) may be preferable to cryotherapy in terms of pain, healing, and recurrence rate (up to 20% with ED&C).

 

Photodynamic therapy (PDT) is also successful with Bowen’s disease by the virtue of being able to treat large areas. Despite the reports of superior cosmesis and healing, PDT can have associated erythema, edema, and pain. It requires one, two, or more treatments with a clearance rate of up to 90% and recurrence rate of 10-20% or higher.

 

Various radiotherapy techniques have been used to treat Bowen’s disease. Response of up to 100% has been documented with recurrence rates of 0-10%. Limitations of radiotherapy has been non-healing on the lower leg of up to 20%. However, in those studies, larger energies have been utilized (100 and 120 kVa). This compares to current recommendations of 50-80 kVA of superficial radiotherapy where such complications can be avoided.

 

Finally, Mohs surgery remains the gold standard for treatment of Bowen’s disease except for small trunk and extremity lesions. It had a 6-8% recurrence rate. It is particularly effective for previously treated and recurrent Bowen’s disease.

 

Topical and destructive therapies have the potential to partially clear the lesion creating noncontiguous ‘‘skip’’ tumors. Aggressive surgical treatment would be required to achieve cure then. There is an additional risk to non-surgical treatments that must be considered – areas of invasive carcinoma within squamous cell carcinoma in situ. Additional sampling biopsies can help with that assessment, but ultimately clinical suspicion should guide the management.

Related Articles

Recurrent-SCC-nose-rhinectcomy-mapping-biopsy-SCARS-center-Mohs-excision-infiltrative-squamous-cell
Recurrent SCC of Nasal Tip
HISTORY 71-year-old man presents with recurrence of SCC of nose following Mohs excision on 2-9-17. Partial rhinectomy was performed with incomplete Mohs excision leaving residual positive margins due to patient’s comfort.  Two additional excisions of involved margins were done under anesthesia achieving clear margins. First stage reconstruction was performed on 4-11-18. DISCUSSION Management of a…
Read More
Recurrent-SCC-of-Nasal-Tip-Orange-County-Skin-Cancer
Recurrent SCC of Nasal Tip
HISTORY 71-year-old man presents with recurrence of SCC of left nose. Mohs excision of left nasal tip SCC was performed on 2-9-17. Left nasal fullness under flap, initially thought to be a scar, progressed until drainage appeared. Pathology of draining debris under flap showed invasive squamous cell carcinoma.  Intranasal mapping biopsies were performed on 2-12-18.…
Read More
Skin-Cancer-And-Reconstructive-Surgery-Foundation-Forehead-SCC-with-perineural-invasion-Beam’s-eye-view
Forehead SCC with Perineural Invasion
HISTORY   83-year-old man presented in 02/2017 with a 3-year history of a forehead and temple SCC. The cancer was initially treated with cryoablation and 5-FU. Excision on 9/2/16 was performed with residual circumferential margins. Histology found poorly differentiated sclerosing squamous cell carcinoma, with perineural invasion of 0.1 mm nerves.  Wide local resection with radial…
Read More
Skin-Cancer-And-Reconstructive-Surgery-Foundation-Scalp-SCC-Metastasis-to-neck-CT-PET-scan
Scalp SCC Metastasis to Neck
HISTORY   64-year-old man presents in 11/2017 with tender, right postauricular swelling. Fine needle aspiration biopsy showed squamous cell carcinoma. Extensive squamous cell carcinoma of scalp was treated with 4 levels of Mohs earlier that year in 01/2017. Additional smaller squamous cell carcinoma of the same area of the scalp was treated with Mohs in…
Read More
Deeply-Invasive-Squamous-Cell-Carcinoma-of-Cheek-Skin-Cancer-And-Reconstructive-Surgery-Foundation-Skin-Cancer-Conference-August-2017
Deeply Invasive Squamous Cell Carcinoma of Cheek
  HISTORY: 82-year-old man with a 1 year history of squamous cell carcinoma on the right lower cheek biopsied on 4/28/2017. Radical resection of the right cheek carcinoma and deep facial lymph node biopsy was performed. Intraoperative Mohs margin evaluation confirmed clear margins. Final permanent histology margins were close but clear. Evidence of perineural invasion…
Read More
SCARS-Center-Metastatic-Squamous-Cell-Carcinoma-Skin-cancer-jaw
Metastatic Squamous Cell Carcinoma
HISTORY 76-year-old man with a rapidly growing mass on angle of jaw. Fine needle aspiration on 12/6/16 diagnosed squamous cell carcinoma. The presumptive primary carcinoma was skin. On 12/16/16, the patient underwent a left parotidectomy and cervical lymphadenectomy. Pathology showed multiple lymph node involvement. Radiation and concurrent chemotherapy treatment began on 1/18/2017 and was completed…
Read More

STAY UP TO DATE

Receive research updates, inspiring stories, healthy living tips and more.

Something went wrong. Please check your entries and try again.

FOLLOW US

ELEVATING THE STANDARDS OF SKIN CANCER MANAGEMENT.

© 2018 SCARS Management Services. All rights reserved.